took a beating after it's guidance underwhelm last quarter.
I do believe that the reaction was overdone.
has healthy revenue streams and growing drug and generics demand.
TA confirms a re-entering into trading range of:
PT 1: $25.00 for a ~20%+ return.
PT 2: $30.00 for a 50% return.